NCT04028531 Understanding Chronic Lymphocytic Leukemia
| NCT ID | NCT04028531 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dana-Farber Cancer Institute |
| Condition | Chronic Lymphocytic Leukemia |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,750 participants |
| Start Date | 1999-09-29 |
| Primary Completion | 2030-09-29 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,750 participants in total. It began in 1999-09-29 with a primary completion date of 2030-09-29.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to collect human Chronic Lymphocytic Leukemia tissue samples and medical information, in order to find out more about the causes and biology of chronic lymphocytic leukemia.
Eligibility Criteria
Inclusion Criteria: * New and existing patients seen for treatment of monoclonal B-cell lymphocytosis * Any low grade lymphoproliferative disorder * Chronic Lymphocytic Leukemia in the Dana Farber Cancer Institute Hematologic Oncology Clinic or elsewhere Exclusion Criteria: \-
Contact & Investigator
Jennifer Brown, MD,PhD
PRINCIPAL INVESTIGATOR
Dana-Farber Cancer Institute
Frequently Asked Questions
Who can join the NCT04028531 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Lymphocytic Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04028531 currently recruiting?
Yes, NCT04028531 is actively recruiting participants. Contact the research team at Jennifer_brown@dfci.harvard.edu for enrollment information.
Where is the NCT04028531 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT04028531 clinical trial?
NCT04028531 is sponsored by Dana-Farber Cancer Institute. The principal investigator is Jennifer Brown, MD,PhD at Dana-Farber Cancer Institute. The trial plans to enroll 2,750 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.